Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 78 points (0.5%) at 16,438 as of Thursday, March 6, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,775 issues advancing vs. 1,148 declining with 152 unchanged. The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.4%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 2.3%, Mylan ( MYL), down 1.5% and Actavis ( ACT), down 1.5%. Top gainers within the industry include Teva Pharmaceutical Industries ( TEVA), up 1.6%, AbbVie ( ABBV), up 1.2%, Novartis ( NVS), up 1.2%, Merck ( MRK), up 1.0% and Amgen ( AMGN), up 0.5%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. GlaxoSmithKline ( GSK) is one of the companies pushing the Drugs industry lower today. As of noon trading, GlaxoSmithKline is down $0.37 (-0.7%) to $56.06 on average volume. Thus far, 1.0 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $55.96-$56.33 after having opened the day at $56.30 as compared to the previous trading day's close of $56.43. GlaxoSmithKline plc manufactures and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $137.0 billion and is part of the health care sector. Shares are up 5.7% year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst that rates GlaxoSmithKline a buy, no analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full GlaxoSmithKline Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.